Structural basis for serpin inhibitor activity

Proteins: Structure, Function, and Bioinformatics

Volumn 22, Issue 3, 1995, Pages 210-225

  Wright, H Tonie ^a   Scarsdale, J Neel ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

deamidation; homology modeling; mutants; serpin proteinase complex; helix sheet conversion

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTITHROMBIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR;

ARTICLE; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; ENZYME STABILITY; POINT MUTATION; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; STRUCTURE ACTIVITY RELATION;

ALPHA 1-ANTITRYPSIN; AMINO ACID SEQUENCE; ANTIPLASMIN; BINDING SITES; COMPUTER GRAPHICS; HYDROGEN BONDING; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; SERPINS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0029050316     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.340220303     Document Type: Article

References (97)

1. Human plasma proteinase inhibitors
2. 1‐Antitrypsin and the serpins:Variation and countervariation
3. 1‐antitrypsin, antithrombin and the mechanism of inflammatory thrombosis
4. Crystal structure of plakalbumin, a proteolytically nicked form of ovalbumin
5. 1‐proteinase inhibitor: Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function
6. Implications of the three‐dimensional structure and function of serpins
7. Crystal structure of cleaved bovine antithrombin III at 3.2Å resolution
8. 1‐antichymotrypsin at 2.7Å resolution and its comparison with other serpins
9. Crystal structure of cleaved equine leucocyte elastase inhibitor determined at 1.95Å resolution
10. On the size of the active site in ‐ proteases
11. Crystal structure of ovalbumin as a model for the reactive centre ofserpins
12. Mobile reactive centre of serpins and the control of thrombosis
13. Substrate properties of C1 inhibitor Ma (alanine 434 →glutamic acid). Genetic and structural evidence suggesting that the P12 region contains critical determinants of serine protease inhibitor/substrate status
14. Effects of mutations in the hinge region of serpins
15. Structural basis of latency in plasminogen activator inhibitor‐1
16. The intact and cleaved human antithrombin III complex as a model for serpin‐proteinase interactions
17. Biological implications of a 3Å structure of dimeric antithrombin
18. 1 proteinase inhibitor
19. Tertiary templates for proteins Dse of packing criteria in the enumeration of allowed sequences for different structural classes
20. Heparin and ionic strength‐dependent conversion of antithrombin III from an inhibitor to a substrate of α‐thrombin
21. 1‐antichymotrypsins
22. Mechanism of serpin action: Evidence that C1 inhibitor functions as a suicide substrate
23. Antichymotrypsin interaction with chymotrypsin
24. 1‐antichymotrypsin
25. Crystal structure of an uncleaved serpin reveals the conformation of an inhibitory reactive loop
26. Correlation among sites of limited proteolysis, enzyme accessibility and segmental mobility
27. Limited proteolysis of globular proteins occurs at exposed and flexible loops
28. Molecular recognition: Conformational anaiysis oflimited proteolytic sites and serine proteinase inhibitors
29. Modeling studies of the change in conformation required for cleavage of limited proteolytic sites
30. The disappearance of enzymeinhibitor complexes from the circulation of man
31. 2‐antiplasmin as a model for the demonstration of complex reversibility in serpins
32. Evidence of a tetrahedral intermediate complex during serpin‐proteinase interactions
33. Studies on human plasma C1 inactivator‐enzyme interactions. I Mechanisms of interaction with CIs, plasmin and trypsin
34. A simplified procedure for the purification of C1‐inactivator from human plasma
35. 1‐antichymotrypsin: Purification and properties
36. On the properties of porcine elastase released from its complex with human alpha‐1antitrypsin by alkaline cleavage
37. Protection ofhuman plasma kallikrein from inactivation by C1 inhibitor and other protease inhibitors. The role of high molecular weight kininogen
38. Isolation and functional properties of the heavy and light chains of human plasma kallikrein
39. Heparin‐stimulated modification of C1‐inhibitor by subcomponent C1s of human complement
40. Inactivation of factor XII active fragment in normal plasma
41. Human plasma kallikrein and C1‐inhibitor form a complex possessing an epitope that is not detectable on the parent molecules: Demonstration using a monoclonal antibody
42. Changes in protein conformation and stability accompany complex formation between C1 inhibitor and C1‐s
43. Studies on the interactions of human pancreatic elastase 2 with human alpha‐1‐proteinase inhibitor and alpha‐1‐antichymotrypsin
44. Alteration of serpin specificity by a protein cofactor
45. Properties of thrombin‐ and elastase‐modified human antithrombin III
46. Plasma serine proteinase inhibitors (serpins) exhibit major conformation changes and a large increase in conformational stability upon cleavage at their reactive sites
47. 1‐proteinase inhibitor by tetranitromethane
48. 1‐proteinase inhibitor in β‐sheet A
49. Conversion of antithrombin from an inhibitor of thrombin to a substrate with reduced heparin affinity and enhanced conformational stability by binding of a tetradecapeptide corresponding to the PI to P14 region of the putative reactivebond loop of the inhibitor
50. 1‐proteinase inhibitor probed by limited proteolysis
51. 1antichymotrypsin into a human neutrophil elastase inhibitor:Demonstration of variants with different association rate constants, stoichiometries of inhibition, and complex stabilities
52. Immunologic evidence for insertion of the reactive‐bond loop of antithrombin into the A β‐sheet of the inhibitor during trapping of target proteinases
53. Antithrombin Cambridge, 384 Ala to Pro: A new variant identified using the polymerase chain reaction
54. Molecular characterization of antithrombin III (ATIII) variants using polymerase chain reaction
55. 384→Pro mutation with abnormal thrombin‐binding activity and thrombotic diseases
56. Antithrombin Vicenza, Ala 384 to Pro (GCA to CCA) mutation, transforming the inhibitor into a substrate
57. Antithrombin‐III‐Hamilton: A gene with a point mutation (guanine to adenine) in codon 382 causing impaired serine protease reactivity
58. Antithrombin‐III‐Hamilton, Ala 282 to Thr: An antithrombin‐III variant that acts as a substrate but not an inhibitor of α‐ thrombin and factor Xa
59. Proteolytically cleaved mutant antithrombin‐Hamilton has high stability to denaturation characteristic of wild type inhibitor serpins
60. Sitedirected mutagenesis of alanine‐382 of human antithrombin III
61. 436 →Thr) results in nonsubstrate‐like behavior and in polymerization of the molecule
62. 2‐Antiplasmin Enschede: Alanine insertion and abolition of plasmin inhibitory activity
63. 2‐antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder
64. 2‐Antiplasmin Enschede is not an inhibitor, but a substrate, of plasmin
65. Ligand binding: Proteinase‐protein inhibitor interactions
66. Allosteric modifiers of hemoglobin. 2. Crystallographically determined binding sites and hydrophobic binding/interaction analysis of novel hemoglobin allosteric oxygen effectors
67. New tools for modeling and understanding hydrophobicity and hydrophobic interactions
68. Plasminogen activator inhibitors
69. Type I plasminogen activator inhibitor
70. The fibrinolytic system of cultured endothelial cells: Deciphering the balance between plasminogen activation and inhibition
71. Nonenzymatic deamidation of asparaginyl and glutaminyl residues in proteins
72. Serpin tertiary structure transformation
73. Identification of a conformationally distinct form of plasminogen activator inhibitor‐I, acting as a non‐inhibitory substrate for tissue‐type plasminogen activator
74. 1‐proteinase inhibitor variant T345R Influence of P14 residue on substrate and inhibitory pathways
75. On the kinetics of the reaction between human antiplasmin and plasmin
76. Alpha‐2‐antiplasmin: A serpin with two separate but overlapping reactive sites
77. 1‐antitrypsin, antithrombin and the mechanism of inflammatory thrombosis
78. Absence of large‐scale conformational change upon limited proteolysis of ovalbumin, the prototypic serpin
79. Ovalbumin and angiotensinogen lack serpin S‐R conformational change
80. Preparation and characterization of monoclonal antibodies against the human thrombin‐antithrombin III complex
81. A monoclonal antibody that triggers dpacylation of an intennediate thrombin‐antithrombin III complex
82. Hydrophobic residues 382‐386 of antithrombin III, Ala‐Ala‐Ala‐Ser‐Thr, serve as the epitope for an antibody which facilitates hydrolysis of the inhibitor by thrombin
83. 1‐antitrypsin by a peptide sequentially similar to beta‐strand s4A
84. 1 proteinase inhibitor variants
85. Conversion of plasminogen activator inhibitor‐l from inhibitor to substrate by point mutations in the reactive‐site loop
86. Dissociation of heparin‐dependent thrombin and factor Xa inhibitory activities of antithrombin‐III by mutations in the reactive site
87. 1s by a myxoma virus serine proteinase inhibitor
88. The Protein Data Bank: A computerbased archival file for macromolecular structures
89. 2antiplasmin‐protease complexes in mice
90. 2‐macroglobulin‐methylamine
91. 1‐proteinase inhibitor and antithrombin III
92. 1‐proteinase inhibitor, antithrombin III and heparin cofactor II
93. Serpin receptor 1: A hepatic receptor that mediates the clearance of antithrombin III‐proteinase complexes
94. Identification of a serpin‐enzyme complex receptor on human hepatoma cells and human monocytes
95. 1antitrypsin‐protease complexes is mediated by the serpinenzyme complex (SEC) receptor
96. 2‐antiplasmin, angiotensinogen, and ovalbumin
97. 1 AT*